Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420162 | 0.91 | KDM4E (0.61) | MEN1KMT2ABACE1KDM4EALDH1A1 | |
| SCHEMBL9726036 | 0.79 | MEN1 (0.50) | MEN1KMT2ABACE1KDM4EALDH1A1 | |
| SCHEMBL10569299 | 0.76 | ALDH1A1 (0.51) | MEN1KMT2ABACE1KDM4EALDH1A1 | |
| SCHEMBL17376012 | 0.73 | COMT (0.49) | MEN1KMT2ABACE1KDM4EALDH1A1 | |
| SCHEMBL10567037 | 0.73 | ALDH1A1 (0.43) | MEN1KMT2ABACE1KDM4EALDH1A1 | |
| SCHEMBL15707630 | 0.72 | DRD1 (0.60) | MEN1KMT2AKDM4EALDH1A1ATM | |
| SCHEMBL6733562 | 0.71 | CA1 (0.79) | BACE1KDM4EALDH1A1MAPTTDP1 | |
| SCHEMBL197522 | 0.71 | CA1 (0.79) | BACE1KDM4EALDH1A1MAPTTDP1 | |
| SCHEMBL9151672 | 0.71 | CA1 (0.79) | BACE1KDM4EALDH1A1MAPTTDP1 | |
| SCHEMBL28937901 | 0.71 | ERN1 (0.49) | MEN1KMT2ABACE1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2297133-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | MEN1 2898/4885KMT2A 2279/4885BACE1 48/4885 |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | MEN1 2898/4885KMT2A 2279/4885BACE1 48/4885 |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | MEN1 2898/4885KMT2A 2279/4885BACE1 48/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | MEN1 2898/4885KMT2A 2279/4885BACE1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.